Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis

Journal of Clinical Psychopharmacology

Volumn 37, Issue 1, 2017, Pages 46-53

  Yoon, Seoyoung ^a   Jeon, Sang Won ^a   Ko, Young Hoon ^a   Patkar, Ashwin A ^b   Masand, Prakash S ^c   Pae, Chi Un ^d   Han, Changsu ^a  

^a Korea University   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Academy of Medicine Singapore   (Singapore)

^d The Catholic University of Korea   (South Korea)

Author keywords

brexpiprazole; efficacy; major depressive disorder; meta analysis; OPC 34712; tolerability

Indexed keywords

ANTIDEPRESSANT AGENT; BREXPIPRAZOLE; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; THIOPHENE DERIVATIVE;

AKATHISIA; BODY WEIGHT DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; SYSTEMATIC REVIEW; WEIGHT GAIN;

DEPRESSIVE DISORDER, MAJOR; HUMANS; QUINOLONES; SEROTONIN AGENTS; THIOPHENES;

EID: 85004011508     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000622     Document Type: Review

References (58)

1. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: III. Pharmacotherapy. J Affect Disord. 2009;117(suppl 1):S26-S43.
2. Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71:43-64.
3. Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76: 487-498.
4. Wen XJ, Wang LM, Liu ZL, et al. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. Braz J Med Biol Res. 2014;47:605-616.
5. Spielmans GI, Berman MI, Linardatos E, et al. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013; 10:e1001403.
6. Pringsheim T, Gardner D, Patten SB. Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks BMJ. 2015;350:h569.
7. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25:109-127.
8. Goldberg JF, Freeman MP, Balon R, et al. The American society of clinical psychopharmacology survey of psychopharmacologists' practice patterns for the treatment of mood disorders. Depress Anxiety. 2015;32:605-613.
9. Berman RM, Thase ME, Trivedi MH, et al. Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011;7: 303-312.
10. Han C, Wang SM, Lee SJ, et al. Optimizing the use of aripiprazole augmentation in the treatment of major depressive disorder: from clinical trials to clinical practice. Chonnam Med J. 2015;51:66-80.
11. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76:1224-1231.
12. Citrome L, Stensbol TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders Expert Rev Neurother. 2015;15:1219-1229.
13. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589-604.
14. Citrome L. TheABC's of dopamine receptor partial agonists-aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69:1211-1220.
15. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76:1232-1240.
16. Cohn LD, Becker BJ. How meta-analysis increases statistical power. Psychol Methods. 2003;8:243-253.
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
18. Kirsch I, Moncrieff J. Clinical trials and the response rate illusion. Contemp Clin Trials. 2007;28:348-351.
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967;6:278-296.
20. Zimmerman M, PosternakMA, Chelminski I. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res. 2004;38:577-582.
21. Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009; 70(suppl 6):26-31.
22. The Cochrane Collaboration. Review Manager 5.3 tutorial. 2014. Available at: http://tech.cochrane.org/revman/download. Accessed January 16, 2016.
23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
24. Krystal A, Mittoux A, Meisels P, et al. Adjunctive brexpiprazole (opc-34712) in patients with major depressive disorder and sleep disturbances: an exploratory study. In: Conference abstract, American Society of Clinical Psychopharmacology. June 22-25, 2015, Miami, FL.
25. Weiller E, Okame T, Perry P, et al. Switching from inadequate adjunctive treatments: open-label study of brexpiprazole effects on depressive symptoms, cognitive and physical functioning. In: Conference abstract, American society of clinical Psychopharmacology. June 22-25, 2015, Miami, FL.
26. FavaM, Ménard F, DavidsenCK, et al.Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry. 2016. doi: 10.4088/JCP.15m10470.
27. Davis L, Ota A, Perry P, et al. Adjunctive brexpiprazole (opc-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study. In: Conference abstract, American Society of Clinical Psychopharmacology. June 22-25, 2015, Miami, FL. 28.
28. Weisler RH, Ota A, Tsuneyoshi K, et al. Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. J Affect Disord. 2016;204:40-47.
29. Thase M, Youakim I, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole (OPC-34712) in major depressive disorder: results of two pivotal clinical studies. Conference abstract, American College of Neuropsychopharmacology; Dec 7-11, 2014, Phoenix, AZ.
30. McIntyre RS, Weiller E, Zhang P, et al. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: results from a post-hoc analysis of two randomised controlled trials. J Affect Disord. 2016;201:116-123.
31. Thase ME, Zhang P, Skuban A, et al. Efficacy and safety of brexpiprazole (opc-34712) as adjunctive treatment in major depressive disorder: metaanalysis of two pivotal studies. In: Conference abstract, American Society of Clinical Psychopharmacology. June 22-25, 2015, Miami, FL.
32. Nelson JC, Skuban A, Hobart M, et al. The metabolic tolerability profile of adjunct brexpiprazole (opc-34712) in major depressive disorder American Society of Clinical Psychopharmacology. June 22-25, 2015, Miami, FL.
33. Fava M, Weiller E, Zhang P, et al. The effect of adjunctive brexpiprazole (opc-34712) on depressive symptoms in patients with irritability: results from post-hoc analyses. In: Conference abstract, American Society of Clinical Psychopharmacology. June 22-25, 2015, Miami, FL.
34. Weiss C, Skuban A, Hobart M, et al. Incidence, onset, duration and severity of akathisia with adjunctive brexpiprazole (opc-34712) in major depressive disorder: analysis of two pivotal studies. Conference abstract, American Society of Clinical Psychopharmacology; June 22-25, 2015, Miami, FL.
35. Thase ME, Fava M, Hobart M, et al. Efficacy of adjunctive OPC-34712 across multiple outcome measures in major depressive disorder: a phase II, randomized, placebo-controlled study. Conference abstract, American College of Neuropsychopharmacology; December 4-8, 2011, Waikoloa, HI.
36. Nelson JC, Skuban A, Zhang P, et al. Long-term safety of adjunctive brexipiprazole (OPC-34712) in MDD: Results from two 52-week open-label studies. Conference abstract, 168th American Psychiatric Association Annual Meeting; May 16-20, 2015, Toronto, ON, Canada.
37. GRADEpro GDT. GRADEpro Guideline Development Tool [software] (developed by Evidence Prime, Inc). Available at: gradepro.org. Accessed May 17, 2016.
38. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett. 2005;387:157-161.
39. Chen TY, Tzeng NS. Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects. Med Hypotheses. 2013;81:183-185.
40. Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27:703-716.
41. Mnie-Filali O, Faure C, Lambas-Senas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology. 2011;36:1275-1288.
42. Canale V, Kurczab R, Partyka A, et al. Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: multiobjective based design, synthesis, and antidepressant and anxiolytic properties. Eur J Med Chem. 2016;108:334-346.
43. Muguruza C, Rodríguez F, Rozas I, et al. Antidepressant-like properties of three new 2-adrenoceptor antagonists. Neuropharmacology. 2013;65:13-19.
44. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540-549.
45. Waters KA, Stean TO, Hammond B, et al. Effects of the selective 5-HT (7) receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res. 2012;228:211-218.
46. Cifariello A, Pompili A, Gasbarri A. 5-HT(7) receptors in the modulation of cognitive processes. Behav Brain Res. 2008;195:171-179.
47. Horisawa T, Nishikawa H, Toma S, et al. The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone. Behav Brain Res. 2013;244:66-69.
48. Kusek M, Sowa J, Kaminska K, et al. 5-HT7 receptor modulates GABAergic transmission in the rat dorsal raphe nucleus and controls cortical release of serotonin. Front Cell Neurosci. 2015;9:324.
49. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood Eur J Neurosci. 2009; 29:1795-1809.
50. Sharpley AL, Cowen PJ. Effect of pharmacologic treatments on the sleep of depressed patients. Biol Psychiatry. 1995;37:85-98.
51. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015;25:356-364.
52. Yoshimi N, Fujita Y, Ohgi Y, et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacol Biochem Behav. 2014;124:245-249.
53. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:605-614.
54. Das S, Barnwal P, Winston AB, et al. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6:39-54.
55. Correll CU, SkubanA, Ouyang J, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind placebo-controlled trial. Am J Psychiatry. 2015;172:870-880.
56. Pae CU. A reviewof the safety and tolerability of aripiprazole. Expert Opin Drug Saf. 2009;8:373-386.
57. Chaudhry I, NeelamK, Duddu V, et al. Ethnicity and psychopharmacology. J Psychopharmacol. 2008;22:673-680.
58. Patra S. Tardive dyskinesia and covert dyskinesia with aripiprazole: a case series. Curr Drug Saf. 2016;11:102-103.